|
|
|
|
Phase III Study Showed Lucentis Improved Vision In Patients With Branch Retinal Vein Occlusion
Genentech, Inc.announced today that the Phase III study BRAVO showed Lucentis (ranibizumab injection) improved vision, as measured by the primary endpoint of mean change from baseline in best-corrected visual acuity at six months, in...
|
|
|
Phase-III study shows Lucentis improves vision in branch retinal vein occlusion
Roche announced that the phase-III study BRAVO showed Lucentis (ranibizumab injection) improved vision, as measured by the primary endpoint of mean change from baseline in best-corrected visual acuity at six months, in patients with macular ...
|
|
|
Genentech's Phase III retinal vein occlusion trial meets endpoint
(Datamonitor via COMTEX) -- DNA | Quote | Chart | News | PowerRating -- Genentech, a biotechnology company, has reported that the Phase III study Bravo showed Lucentis improved vision, as measured by the primary endpoint of mean change from...
|
|
|
FDA approves implant for macular edema associated with RVO
Source: Ophthalmology Times E-News Email|Print| Del.icio.us Digg Reddit Facebook |Save|License Irvine, CAThe FDA has approved dexamethasone intravitreal implant 0.7 mg (Ozurdex, Allergan) for the treatment of macular edema following...
|
|
|
Jul 2, 2009
-- Genentech, Inc.announced today that the Phase III study BRAVO showed Lucentis (ranibizumab injection) improved vision, as measured by the primary endpoint of mean change from baseline in best-corrected visual acuity at six months, in...
|
|
|
FDA approves new IV iron therapy for CKD
The drug is not yet approved for an oncology setting.Print Email Discuss in our forum The FDA has approved ferumoxytol injection for intravenous use as an iron replacement therapy for the treatment of iron deficiency anemia in adult...
|
|
|
UPDATE 1-Roche's Lucentis found to curb retinal occlusion
LOS ANGELES, July 2 (Reuters) - Monthly injections of Roche Holding AG's Lucentis can significantly improve sight in people with retinal vein occlusion, which leads to vision loss, according to research released by the company's Genentech...
|
|
|
Genentech says Lucentis succeeded late stage trial
Genentech says Lucentis injections improved vision for patients with macular edema Buzz up!Companies: SOUTH SAN FRANCISCO, Calif! (AP) -- Genentech Inc. said Thursday its macular degeneration drug Lucentis met its goal in a late...
|
|
|
Genentech says Lucentis injections improved vision for patients with macular edema
SOUTH SAN FRANCISCO, Calif.(AP) - Genentech Inc. said Thursday its macular degeneration drug Lucentis met its goal in a late stage trial, improving the vision of patients with macular edema. Lucentis is approved to treat macular...
|
|
|
Genentech says Lucentis met goal in clinical trial
Genentech says Lucentis injections improved vision for patients with macular edema Buzz up!Companies: SOUTH SAN FRANCISCO, Calif! (AP) -- Genentech Inc. said Thursday its macular degeneration drug Lucentis met its goal in a late...
|
|
|
Genentech says Lucentis succeeded late stage trial
SOUTH SAN FRANCISCO, Calif.(AP) -- Genentech Inc. said Thursday its macular degeneration drug Lucentis met its goal in a late stage trial, improving the vision of patients with macular edema. Lucentis is approved to treat...
|
|
|
Genentech says Lucentis succeeded late stage trial
SOUTH SAN FRANCISCO, Calif.- Genentech Inc. said Thursday its macular degeneration drug Lucentis met its goal in a late stage trial, improving the vision of patients with macular edema due to branch retinal vein occlusion.
|
|
|
Genentech says Lucentis met goal in clinical trial
SOUTH SAN FRANCISCO, Calif.- Genentech Inc. said Thursday its macular degeneration drug Lucentis met its goal in a late stage trial, improving the vision of patients with macular edema due to branch retinal vein occlusion.
|
|
|
Genentech says Lucentis met goal in clinical trial
SOUTH SAN FRANCISCO, Calif.(AP) -- Genentech Inc. said Thursday its macular degeneration drug Lucentis met its goal in a late stage trial, improving the vision of patients with macular edema due to branch retinal vein occlusion.
|
|
|
iCo Therapeutics Publishes Review of Diabetic Retinopathy Treatment
VANCOUVER, July 2 /CNW/ - iCo Therapeutics Inc.(TSX-V: ICO) today announced that iCo-007, iCo's lead Diabetes Macular Edema candidate, has been featured in an article in the Journal of Diabetes Science and Technology, a peer...
|
|
|
iCo Therapeutics Publishes Review of Diabetic Retinopathy Treatment
VANCOUVER, July 2 /CNW/ - iCo Therapeutics Inc.(TSX-V: ICO) today announced that iCo-007, iCo's lead Diabetes Macular Edema candidate, has been featured in an article in the Journal of Diabetes Science and Technology, a peer...
|
|
|
Phase III Study Showed Lucentis Improved Vision in Patients with Branch Retinal Vein Occlusion
-- BRAVO evaluated the safety and efficacy of six monthly injections of Lucentis compared to monthly sham injections.The two doses of Lucentis studied showed a statistically significant improvement in best-corrected visual acuity (the...
|
|
|
Phase III Study Showed Lucentis Improved Vision in Patients with Branch Retinal Vein Occlusion
Companies mentioned in this article: Genentech, Inc.SOUTH SAN FRANCISCO, Calif. -- (BUSINESSWIRE) -- Genentech, Inc. announced today that the Phase III study BRAVO showed Lucentis (ranibizumab injection) improved vision, as measured...
|
|
|
Phase III Study Showed Lucentis Improved Vision in Patients with Branch Retinal Vein Occlusion
- Genentech, Inc.announced today that the Phase III study BRAVO showed Lucentis (ranibizumab injection) improved vision, as measured by the primary endpoint of mean change from baseline in best-corrected visual acuity at six months, in...
|
|
|
Phase III Study Showed Lucentis Improved Vision in Patients with Branch R
Genentech, Inc.announced today that the Phase III study BRAVO showed Lucentis (ranibizumab injection) improved vision, as measured by the primary endpoint of mean change from baseline in best-corrected visual acuity at six months, in...
|
|
|
Phase III Study Showed Lucentis Improved Vision in Patients with Branch Retinal Vein Occlusion
BusinessWire - Genentech, Inc.announced today that the Phase III study BRAVO showed Lucentis(R) (ranibizumab injection) improved vision, as measured by the primary endpoint of mean change from baseline in best-corrected visual acuity at...
|
|
|
Phase III Study Showed Lucentis Improved Vision in Patients with Branch Retinal Vein Occlusion
Study Showed Early and Sustained Improvement in Vision Through Six Months -- ) SOUTH SAN FRANCISCO, Calif., Jul 02, 2009 (BUSINESS WIRE) -- Genentech, Inc.announced today that the Phase III study BRAVO showed Lucentis(R) (ranibizumab...
|
|
|
Phase III Study Showed Lucentis Improved Vision in Patients with Branch Retinal Vein Occlusion
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, Inc.announced today that the Phase III study BRAVO showed Lucentis (ranibizumab injection) improved vision, as measured by the primary endpoint of mean change from baseline in best...
|
|
|
Phase III Study Showed Lucentis Improved Vision in Patients with Branch Retinal Vein Occlusion
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- Genentech, Inc.announced today that the Phase III study BRAVO showed Lucentis(R) (ranibizumab injection) improved vision, as measured by the primary endpoint of mean change from baseline in...
|
|
|
Phase III Study Showed Lucentis Improved Vision in Patients with Branch Retinal Vein Occlusion
-- Study Showed Early and Sustained Improvement in Vision Through Six Months -- SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, Inc.announced today that the Phase III study BRAVO showed Lucentis (ranibizumab injection) improved...
|
